{
    "nct_id": "NCT04601402",
    "official_title": "A Phase I/Ib Study to Evaluate the Safety, Tolerability, Biological and Clinical Activities of GEN-001 in Combination With Avelumab in Patients With Advanced Solid Tumors Who Have Progressed During or After Treatment With Anti-PD-(L)1 Therapy",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate organ functions as defined in the protocol\n* Negative childbearing potential\n* Have ability to swallow and retain oral medication and no clinically significant gastrointestinal abnormalities\n* Patients with diseases for which no curative therapies are available, and who have progressed on at least two lines of approved therapy for their histological subtypes which includes an anti-PD-1 or anti-PD-L1 based therapy (as mono or combination)\n* Disease progression on anti-PD-(L)1 based therapy (as monotherapy or combination therapy) and must meet criteria for acquired resistance as defined in the protocol\n* Patients who have completely recovered from any clinically significant AEs that occurred during prior immunotherapy\n* Estimated life expectancy of at least 3 months\n* Objective evidence of disease progression at baseline (Dose Escalation)\n* Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic NSCLC, SCCHN, and UC (Dose Expansion)\n* Measurable disease as per RECIST v1.1 defined as at least 1 lesion (Dose Expansion)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have experienced primary resistance to anti-PD-(L)1 based therapy\n* Has experienced a toxicity that led to permanent discontinuation of prior anti-PD-(L)1 based therapy or other immunotherapies\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Current use of immunosuppressive medication at time of study entry\n* Have an active infection requiring antibiotics, antifungal or antiviral agents or have received a course of antibiotics within the previous 4 weeks of starting study treatment\n* Has received a live vaccine within 4 weeks of starting of study treatment\n* Known history of, or any evidence of active, non-infectious pneumonitis\n* Prior solid organ or allogeneic stem cell transplantation\n* Has had any investigational or anti-tumor treatment within 4 weeks or 5 half-life periods of starting study treatment, had any major surgeries within 4 weeks of starting study treatment\n* Has received proton pump inhibitors (PPIs) within 2 weeks prior to dosing study treatments\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has clinically significant (i.e., active) cardiovascular disease\n* Has known history of uncontrolled intercurrent illness\n* Has any psychiatric condition that would prohibit the understanding or rendering of informed consent or that would limit compliance with study requirements.",
    "miscellaneous_criteria": ""
}